The UK’s system for pricing drugs is to move from one based on controlling profits to a value-based approach. The switch has implications for other countries in Europe.
The light and dark blues have found new competitive pursuit that doesn't involve rowing down The Thames, or fighting in the Twickenham mud -- innovation.
The first programme in a multinational scheme to generate vaccines needed in the developing world by guaranteeing a market in advance of their development has got under way.